Is Fresenius Medical Care AG & Co. KGaA (FMS) a Buy, Sell, or Hold?
NYSE : FMS
Fresenius Medical Care AG & Co. KGaA
$24.11 USD
$0.02 (0.08%)
- Volume
- 500.09K
- Average Volume
- 753.06K
- Market Capitalization
- $12.95B
- P/E Ratio
- 12.88
- Dividend Yield
- 3.53%
- Price Target
- $19.85
- Year High
- $27.64
- Year Low
- $20.02
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.45
- Current Ratio
- $1.20
Company Overview
NYSE
Helen Giza
Medical - Care Facilities
Healthcare
FMS
108165
DE
USD
Liquidity Metrics
0.83
1.20
0.86
0.18
0.45
Sales & Valuation
$19.63B
0.59
0.88
6.35
3.24
Profitability
$1.68
$978.37M
4.88%
7.59%
7.16%
3.00%
P/E Metrics
12.88
0.24
0.24
Analyst Price Target & Rating
$19.85
$28.00
$11.70
3/5
20 Analysts
21.46%
Poll Results
About Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Stock
Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Through an extensive network of outpatient clinics, it delivers essential dialysis therapy along with laboratory and diagnostic support. For home-based care, the company supplies necessary equipment, provides comprehensive training, and offers ongoing patient assistance, including clinical oversight and coordinating supply deliveries directly to patients. In the United States, Fresenius Medical Care also contracts with hospitals to provide vital dialysis interventions for hospitalized individuals suffering from end-stage renal disease (ESRD) and acute kidney failure. Beyond services, it is a pro ... minent developer, manufacturer, and distributor of a broad range of dialysis products. This portfolio encompasses polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers and solutions, concentrates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, the company produces non-dialysis medical devices, including acute cardiopulmonary and apheresis products. Its pharmaceutical division focuses on developing, acquiring, and in-licensing specialized renal medications, distributing these essential drugs and supplies to both individual patients' homes and dialysis centers. The company also extends its medical offerings to include a variety of specialized services such as vascular, cardiovascular, and endovascular care, operating ambulatory surgery centers for vascular procedures, and providing physician services in nephrology and cardiology. Products are sold directly to dialysis clinics, hospitals, and specialized treatment centers, complemented by sales through local teams, independent distributors, dealers, and agents. By February 23, 2022, Fresenius Medical Care managed an impressive network of 4,171 outpatient dialysis clinics across roughly 150 countries. Established in 1996, the company maintains its headquarters in Bad Homburg, Germany.
Fresenius Medical: High Yield, Utilities-Like Stock At Valuation Lows
2026-07-11 05:28:48
FMS is a defensive dialysis services provider with stable and recurring demand and regulated pricing. Profitability is recovering as FME25+ cost savings flow through the business. The stock offers attractive shareholder returns through high free cash flow, dividends, and large buybacks.
Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now
2026-07-08 15:05:27
FMS??? margin gains, HighVolumeHDF rollout and AI-driven care are boosting momentum, but reimbursement and volume risks remain.
DVA vs. FMS: Which Dialysis Leader Is Better Positioned Now?
2026-06-23 14:21:09
DaVita and Fresenius Medical Care are taking different paths in kidney care, but which stock offers stronger upside now? Let's dive in.
2026-06-22 05:00:00
One of the Largest Identified Graphite Deposits Globally with 120.2 Mt Indicated at 10.27% Cg and 24.1 Mt Inferred at 9.88% Cg, Containing 14.7 Mt of In-Situ Graphite Ottawa, Ontario--(Newsfile Corp. - June 22, 2026) - Focus Graphite Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the "Company"), a Canadian developer of high-grade flake graphite deposits and advanced graphite materials for battery, defence, and industrial applications, is pleased to announce that it has filed the report on SEDAR+ for the upgraded mineral resource estimate ("MRE") on its 100%-owned Lac Tetepisca Project (the "Project") in Quebec. The Project lies within the Nitassinan (ancestral land) of the Pessamit Innu First Nation of Betsiamites, Quebec.
Focus Graphite Completes Final Major ESIA Technical Study, Advancing Lac Knife Toward Permitting
2026-06-15 05:00:00
Hydrogeological Assessment Concludes Multi-Year Environmental Program and Supports Upcoming ESIA Submission Ottawa, Ontario--(Newsfile Corp. - June 15, 2026) - Focus Graphite Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the "Company") a Canadian developer of high-grade flake graphite deposits and advanced graphite materials for battery, defence, and industrial applications, is pleased to announce the completion of the Hydrogeological Assessment (the "Assessment" or the "Study") for its wholly-owned Lac Knife Graphite Project ("Lac Knife" or the "Project"), concluding a multi-year environmental program and completing the major technical work required to support the Company's Environmental and Social Impact Assessment ("ESIA") submission. Completed by Yves Leblanc, P.Geo.
FMS and Home Dialysis: How 5008X Could Reset Demand
2026-06-08 15:56:07
FMS scales 5008X high-volume HDF and expands home dialysis, aiming for benefits later in 2026 and a bigger payoff in 2027+.
FMS Launches kinexus Digital Platform for Home Dialysis Care
2026-06-05 12:35:26
Fresenius Medical Care launches kinexus, a home dialysis platform integrating remote monitoring, prescription management and supply ordering for PD and HHD.
2026-06-03 08:00:00
Global launch of a single, integrated digital platform connecting remote therapy monitoring and operational workflows for home dialysis programs Designed to simplify care processes for healthcare teams and their patients to support high-quality, personalized care for patients dialyzing at home Enables managing peritoneal dialysis and home hemodialysis therapies across Fresenius Medical Care's global home dialysis portfolio in one digital platform BAD HOMBURG, Germany, June 3, 2026 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, today announced the global launch of kinexus, a unified digital platform designed to support home dialysis programs and strengthen connected, patient-centered care. With kinexus, Fresenius Medical Care (FME) is advancing connected home dialysis care by bringing together digital modules supporting peritoneal dialysis (PD) and home hemodialysis (HHD) within a single, unified platform.
Frequently Asked Questions
-
What is the current Fresenius Medical Care AG & Co. KGaA (FMS) stock price?
-
Fresenius Medical Care AG & Co. KGaA(NYSE:FMS) stock price is $24.11 in the last trading session. During the trading session, FMS stock reached the peak price of $27.64 while $20.02 was the lowest point it dropped to. The percentage change in FMS stock occurred in the recent session was 0.08% while the dollar amount for the price change in FMS stock was $0.02.
-
FMS's industry and sector of operation?
-
The NYSE listed FMS is part of Medical - Care Facilities industry that operates in the broader Healthcare sector.
-
Who are the executives of FMS?
-
Charles Hugh-Jones | Global Chief Medical Officer & Member of Management Board
Dominik Heger | Executive Vice President and Head of Investor Relations, Strategic Development & Communications
Jorg Haring | Member of the Management Board, Global Head of Legal,Compliance & Human Resources and Labor Director
Wolfgang Kummerle | Senior Vice President - Quality Management International
Craig Cordola FACHE | Chief Executive Officer of Care Delivery & Member of Management Board -
How many employees does FMS have?
-
Number of FMS employees currently stands at 108165. FMS operates from Else-KrOener Strasse 1, Bad Homburg, HE 61352, DE.
-
Link for FMS official website?
-
Official Website of FMS is: https://www.freseniusmedicalcare.com
-
How do I contact FMS?
-
FMS could be contacted at phone #49 6172 608 2522 and can also be accessed through its website. FMS operates from Else-KrOener Strasse 1, Bad Homburg, HE 61352, DE.
-
How many shares of FMS are traded daily?
-
The average number of FMS shares traded daily for last 3 months was 753.06K.
-
What is the market cap of FMS currently?
-
The market value of FMS currently stands at $12.95B with its latest stock price at $24.11